GSK is emerging from its long convalescence
Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...
The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?
Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...
Top Stock Price Prediction: Strong Tailwinds On Nvidia, GSK, TSCM Stocks
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
Top Stock Price Prediction: Sentiment and Earnings Propel Nvidia, GSK, TSCM Stocks
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
BioSpace1d
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...
carrollspaper.com1d
Stocks, dollar drop as tariff tensions intensify
Stock markets mostly fell, the dollar slid and gold hit a record high Wednesday over fears about a trade war between ...
EconoTimes1d
GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
El Mundo on MSN1d
These are the 11 new best-selling drugs that will transform Medicine in 2025
The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...
GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...
Business Times1d
GSK plans £2 billion share buyback, boosts long-term outlook
GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...